An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 28-35

  Guessous, Fadila ^a   Zhang, Fadila ^a   DiPierro, Charles ^a   Marcinkiewicz, Lukasz ^a   Sarkaria, Jann ^b   Schiff, David ^a   Buchanan, Sean ^c   Abounader, Roger ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b MAYO CLINIC   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SGX 523; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER STEM CELL; CELL ACTIVATION; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; ENZYME INHIBITION; FEEDING; GLIOMA; HUMAN; IN VIVO CULTURE; MEDULLOBLASTOMA; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; PRIMARY TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL; XENOGRAFT;

EID: 77950827990     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009010028     Document Type: Article

References (35)

1. Wen, P. Y.; Kesari, S. Malignant gliomas in adults. N. Engl. J. Med., 2008, 359(5), 492-507.
2. Packer, R. J. Brain tumors in children. Arch. Neurol., 1999, 56(4), 421-425.
3. Mulhern, R. K.; Palmer, S. L.; Merchant, T. E.; Wallace, D.; Kocak, M.; Brouwers, P.; Krull, K.; Chintagumpala, M.; Stargatt, R.; Ashley, D. M.; Tyc, V. L.; Kun, L.; Boyett, J.; Gajjar, A. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J. Clin. Oncol., 2005, 23(24), 5511-5519
4. Reddy, A. T.; Packer, R. J. Medulloblastoma. Curr. Opin. Neurol., 1999, 12(6), 681-685.
5. Ellison, D., Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol. Appl. Neurobiol., 2002, 28(4), 257-282.
6. Taylor, M. D.; Mainprize, T. G.; Rutka, J. T. Molecular insight into medulloblastoma and central nervous system primitive neuroectodermal tumor biology from hereditary syndromes: a review. Neurosurgery, 2000, 47(4), 888-901.
7. Cervoni, L.; Maleci, A.; Salvati, M.; Delfini, R.; Cantore, G. Medulloblastoma in late adults: report of two cases and critical review of the literature. J. Neurooncol., 1994, 19(2), 169-173. (Pubitemid 24252165)
8. Abounader, R.; Laterra, J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-oncology, 2005, 7(4), 436-451.
9. Guessous, F.; Li, Y.; Abounader, R. Signaling pathways in medulloblastoma. J. Cell Physiol., 2008, 217(3), 577-583.
10. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G. F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol., 2003, 4(12), 915-925
11. Li, Y.; Lal, B.; Kwon, S.; Fan, X.; Saldanha, U.; Reznik, T. E.; Kuchner, E. B.; Eberhart, C.; Laterra, J.; Abounader, R. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res., 2005, 65(20), 9355-9362.
12. Rosen, E. M.; Laterra, J.; Joseph, A.; Jin, L.; Fuchs, A.; Witte, M.; Weinarnd, M.; Goldberg, I. D. Scatter factor expression and regulation in human glial tumors. Int. J. Cancer, 1996, 67, 248-255.
13. Koochekpour, S.; Jeffers, M.; Rulong, S.; Taylor, G.; Klineberg, E.; Hudson, E. A.; Resau, J. H.; Vande Woude, G. F. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res., 1997, 57, 5391-5398.
14. Moriyama, T.; Kataoka, H.; Kawano, Y.; Yokogami, K.; Nakano, S.; Goya, T.; Uchino, H.; Koono, M.; Wakisaka, S. Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas. Cancer Lett., 1998, 124, 149-155.
15. Kunkel, P.; Muller, S.; Schirmacher, P.; Stavrou, D.; Fillbrandt, R.; Westphal, M.; Lamszus, K. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neurooncology, 2001, 3(2), 82-88.
16. Laterra, J.; Nam, M.; Rosen, E.; Rao, J. S.; Johnston, P. Scatter factor/hepatocyte growth factor gene transfer to 9L glioma cells enhances glioma growth and angiogenesis in vivo. Lab Invest., 1997, 76(4), 565-577.
17. Laterra, J.; Rosen, E. M.; Nam, M.; Ranganathan, S.; Fielding, K.; Johnston, P. Scatter factor/hepatocyte growth factor expression enhances human glioblastoma tumorigenicity and growth. Biochem. Biophys. Res. Commun., 1997, 235, 743-747. (Pubitemid 27326555)
18. Bowers, D. C.; Fan, S.; Walter, K.; Abounader, R.; Williams, J. A.; Rosen, E. M.; Laterra, J. Scatter factor/hepatocyte growth factor activates AKT and protects against cytotoxic death in human glioblastoma via PI3-kinase and AKT-dependent pathways. Cancer Res., 2000, 60, 4277-4283.
19. Hecht, M.; Papoutsi, M.; Tran, H. D.; Wilting, J.; Schweigerer, L. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res., 2004, 64(17), 6109-6118
20. Brockmann, M. A.; Ulbricht, U.; Gruner, K.; Fillbrandt, R.; Westphal, M.; Lamszus, K. Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery, 2003, 52(6), 1391-9; discussion 1399.
21. Lal, B.; Xia, S.; Abounader, R.; Laterra, J. Targeting the c-Met pathway potentiates glioblastoma responses to gamma-radiation. Clin. Cancer Res., 2005, 11(12), 4479-4486.
22. Abounader, R.; Ranganathan, S.; Lal, B.; Fielding, K.; Book, A.; Dietz, H.; Burger, P.; Laterra, J. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c- met expression. J. Natl. Cancer Inst., 1999, 91(18), 1548-2156
23. Abounader, R.; Lal, B.; Luddy, C.; Koe, G.; Davidson, B.; Rosen, E. M.; Laterra, J. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J., 2002, 16(1), 108-110.
24. Michieli, P.; Mazzone, M.; Basilico, C.; Cavassa, S.; Sottile, A.; Naldini, L.; Comoglio, P. M. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell, 2004, 6(1), 61-73.
25. Sarkaria, J. N.; Yang, L.; Grogan, P. T.; Kitange, G. J.; Carlson, B. L.; Schroeder, M. A.; Galanis, E.; Giannini, C.; Wu, W.; Dinca, E. B.; James, C. D. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol. Cancer Ther., 2007, 6(3), 1167-1174.
26. Lee, J.; Kotliarova, S.; Kotliarov, Y.; Li, A.; Su, Q.; Donin, N. M.; Pastorino, S.; Purow, B. W.; Christopher, N.; Zhang, W.; Park, J. K.; Fine, H. A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell, 2006, 9(5), 391-403.
27. Abounader, R.; Ranganathan, S.; Kim, B. Y.; Nichols, C.; Laterra, J. Signaling pathways in the induction of c-met receptor expression by its ligand scatter factor/hepatocyte growth factor in human glioblastoma. J. Neurochem., 2001, 76(5), 1497-1508.
28. Li, Y.; Guessous, F.; Kwon, S.; Kumar, M.; Ibidapo, O.; Fuller, L.; Johnson, E.; Lal, B.; Hussaini, I.; Bao, Y.; Laterra, J.; Schiff, D.; Abounader, R. PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res., 2008, 68(6), 1723-1731.
29. Kim, K. J.; Wang, L.; Su, Y. C.; Gillespie, G. Y.; Salhotra, A.; Lal, B.; Laterra, J. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res., 2006, 12(4), 1292-1298.
30. Burgess, T.; Coxon, A.; Meyer, S.; Sun, J.; Rex, K.; Tsuruda, T.; Chen, Q.; Ho, S. Y.; Li, L.; Kaufman, S.; McDorman, K.; Cattley, R. C.; Sun, J.; Elliott, G.; Zhang, K.; Feng, X.; Jia, X. C.; Green, L.; Radinsky, R.; Kendall, R. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res., 2006, 66(3), 1721-1729.
31. Abounader, R. Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy. Expert Rev. Anticancer Ther., 2009, 9(2), 235-245.
32. Christensen, J. G.; Schreck, R.; Burrows, J.; Kuruganti, P.; Chan, E.; Le, P.; Chen, J.; Wang, X.; Ruslim, L.; Blake, R.; Lipson, K. E.; Ramphal, J.; Do, S.; Cui, J. J.; Cherrington, J. M.; Mendel, D. B. A selective small molecule inhibitor of c-Met kinase inhibits c-Metdependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res., 2003, 63(21), 7345-7355.
33. Matsumoto, K.; Nakamura, T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer Sci., 2003, 94(4), 321-327.
34. Martens, T.; Schmidt, N. O.; Eckerich, C.; Fillbrandt, R.; Merchant, M.; Schwall, R.; Westphal, M.; Lamszus, K. A novel onearmed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res., 2006, 12(20 Pt 1), 6144-6152.
35. Martin, TA.; Parr, C.; Davies, G.; Watkins, G.; Lane, J.;Matsumoto, K.; Nakamura, T.; Mansel, RE.; Jiang, WG. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis, 2003 24(8),1317-1323